Ekso Bionics

Ekso Bionics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, September 7, 2021

RICHMOND, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investor Conference held on September 13 - 15, 2021.

Key Points: 
  • RICHMOND, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investor Conference held on September 13 - 15, 2021.
  • Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Reports Second Quarter 2021 Results

Retrieved on: 
Thursday, July 29, 2021
Ekso Bionics, NASDAQ, Finance, Health, Technology, Assistive technology

RICHMOND, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2021.

Key Points: 
  • RICHMOND, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended June 30, 2021.
  • Revenue in the second quarter of 2021 included approximately $1.9 million in EksoHealth revenue and approximately $0.3 million in EksoWorks sales.
  • Gross margin was approximately 58% in the second quarter of 2021, compared with gross margin of 56% for the same period in 2020.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics to Report Second Quarter 2021 Financial Results on July 29, 2021

Retrieved on: 
Thursday, July 22, 2021
Articles, Robotics, Technology, Ekso Bionics, Medical robotics, Prosthetics, Powered exoskeleton, Bionics, NASDAQ

RICHMOND, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2021 after the close of trading on Thursday, July 29, 2021.

Key Points: 
  • RICHMOND, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2021 after the close of trading on Thursday, July 29, 2021.
  • ET to discuss the financial results and recent business developments.
  • Founded in 2005, Ekso Bionics continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Exoskeleton Market worth $3,340 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, June 9, 2021
Robotics, Technology, Assistive technology, Medical robotics, Prosthetics, Ekso Bionics, Powered exoskeleton, Exoskeleton, Cyberdyne, Ottobock

The exoskeleton market includes major Tier I and II players like Ottobock (Germany), DIH Medical (China), CYBERDYNE (Japan), Ekso Bionics.

Key Points: 
  • The exoskeleton market includes major Tier I and II players like Ottobock (Germany), DIH Medical (China), CYBERDYNE (Japan), Ekso Bionics.
  • These players have a strong market presence for exoskeleton across various countries in North America, Europe, APAC, and RoW.
  • Thus, the intensifying need for human augmentation in industrial and military sectors creates opportunities for the growth of the exoskeleton market.
  • The high cost of powered exoskeletons leads to a higher market share of the technology compared to passive exoskeletons.

Exoskeleton Market worth $3,340 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, June 9, 2021
Robotics, Technology, Assistive technology, Medical robotics, Prosthetics, Ekso Bionics, Powered exoskeleton, Exoskeleton, Cyberdyne, Ottobock

The exoskeleton market includes major Tier I and II players like Ottobock (Germany), DIH Medical (China), CYBERDYNE (Japan), Ekso Bionics.

Key Points: 
  • The exoskeleton market includes major Tier I and II players like Ottobock (Germany), DIH Medical (China), CYBERDYNE (Japan), Ekso Bionics.
  • These players have a strong market presence for exoskeleton across various countries in North America, Europe, APAC, and RoW.
  • Thus, the intensifying need for human augmentation in industrial and military sectors creates opportunities for the growth of the exoskeleton market.
  • The high cost of powered exoskeletons leads to a higher market share of the technology compared to passive exoskeletons.

Vicarious Surgical Appoints Michael Pratt as Vice President of Commercial Strategy

Retrieved on: 
Thursday, June 3, 2021
Health informatics, Ekso Bionics, Vicarious, Health, Robot-assisted surgery, Medical technology, Articles

WALTHAM, Mass., June 3, 2021 /PRNewswire/ -- Vicarious Surgical Inc. ("Vicarious" or "Vicarious Surgical" or the "Company"), a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, today announced the appointment of Michael Pratt as Vice President of Commercial Strategy.

Key Points: 
  • WALTHAM, Mass., June 3, 2021 /PRNewswire/ -- Vicarious Surgical Inc. ("Vicarious" or "Vicarious Surgical" or the "Company"), a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, today announced the appointment of Michael Pratt as Vice President of Commercial Strategy.
  • Prior to joining Vicarious Surgical, Mr. Pratt served as Global Vice President at Ekso Bionics where he relaunched Ekso's industrial exoskeleton business unit, leading a capital raise as well as executing a managed buyout and scaling within a projected $3 billion market.
  • "Michael's deep commercial expertise within the surgical robotics field will be invaluable as we continue to execute on our strategy to bring our next-generation surgical robotic technology to the market," said Adam Sachs, Co-Founder and Chief Executive Officer of Vicarious Surgical.
  • "I'm thrilled to join the high caliber team at Vicarious Surgical during this period of rapid growth," said Mr. Pratt.

Ekso Bionics® Announces Expanded Partnership with Kindred Healthcare for Multi-Unit EksoNR Order

Retrieved on: 
Tuesday, May 11, 2021
Robotics, Ekso Bionics, Medical robotics, Powered exoskeleton, Health, Kindred Healthcare, Technology, Kindred

b'RICHMOND, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the \xe2\x80\x9cCompany\xe2\x80\x9d), an industry leader in exoskeleton technology for medical and industrial use, today announced an expanded partnership with Kindred Healthcare, LLC ("Kindred") bringing EksoNR, the most clinically used robotic exoskeleton, to four of Kindred\xe2\x80\x99s Long-Term Acute Care (\xe2\x80\x9cLTAC\xe2\x80\x9d) Hospitals in the U.S.

Key Points: 
  • b'RICHMOND, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the \xe2\x80\x9cCompany\xe2\x80\x9d), an industry leader in exoskeleton technology for medical and industrial use, today announced an expanded partnership with Kindred Healthcare, LLC ("Kindred") bringing EksoNR, the most clinically used robotic exoskeleton, to four of Kindred\xe2\x80\x99s Long-Term Acute Care (\xe2\x80\x9cLTAC\xe2\x80\x9d) Hospitals in the U.S.
  • The LTAC locations incorporating EksoNR technology will be at Kindred\xe2\x80\x99s Florida hospitals in Green Cove Springs, Tampa/St.
  • Pete, Fort Lauderdale, and Melbourne.\n\xe2\x80\x9cWe are excited to expand our partnership with Ekso Bionics and build on our leadership position in acute patient services with the addition of these innovative EksoNR devices,\xe2\x80\x9d said Mike Warrington, President of Kindred Healthcare\xe2\x80\x99s Hospital Division.
  • To learn more about Ekso Bionics please visit the Company\xe2\x80\x99s website at www.eksobionics.com or follow @EksoBionics on Twitter.

Ekso Bionics Reports First Quarter 2021 Results

Retrieved on: 
Thursday, April 29, 2021
Ekso Bionics

Revenue in the first quarter of 2021 included approximately $1.7 million in EksoHealth revenue and approximately $0.2 million in EksoWorks sales.\nGross profit for the quarter ended March 31, 2021 was $1.2 million, compared to $0.6 million in the same period in 2020, representing a record gross margin of approximately 65% in the first quarter of 2021, compared to a gross margin for the same period in 2020 of 43%.

Key Points: 
  • Revenue in the first quarter of 2021 included approximately $1.7 million in EksoHealth revenue and approximately $0.2 million in EksoWorks sales.\nGross profit for the quarter ended March 31, 2021 was $1.2 million, compared to $0.6 million in the same period in 2020, representing a record gross margin of approximately 65% in the first quarter of 2021, compared to a gross margin for the same period in 2020 of 43%.
  • For the quarter ended March 31, 2021, the Company used $2.0 million of cash in operations, compared to $1.7 million for the same period in 2020.\nManagement will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.
  • To learn more about Ekso Bionics please visit the Company\xe2\x80\x99s website at www.eksobionics.com or refer to the Company\xe2\x80\x99s Twitter page at @EksoBionics.

Ekso expands its robotic exoskeleton adoption in Asia Pacific

Retrieved on: 
Monday, April 26, 2021
Robotics, Medical robotics, Technology, Ekso Bionics, Science and technology, Assistive technology, Prosthetics, Powered exoskeleton

b'SYDNEY, Australia, April 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics, an industry leader in exoskeleton technology, with its Asia headquarters in Singapore, announces its partnership with Royal Rehab in Australia, further scaling the use of its robotic exoskeleton across the Asia Pacific region.\nEkso is the most clinically used robotic exoskeleton globally and in Asia and has helped patients take more than 130 million steps globally.

Key Points: 
  • b'SYDNEY, Australia, April 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics, an industry leader in exoskeleton technology, with its Asia headquarters in Singapore, announces its partnership with Royal Rehab in Australia, further scaling the use of its robotic exoskeleton across the Asia Pacific region.\nEkso is the most clinically used robotic exoskeleton globally and in Asia and has helped patients take more than 130 million steps globally.
  • Established in 1899, Royal Rehab is highly regarded for its state-wide specialist brain and spinal cord injury rehabilitation.
  • Royal Rehab is managed by an experienced and specialised team dedicated to maximising life skills, abilities, and independence.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.

Ekso expanding its robotic exoskeleton adoption across Asia

Retrieved on: 
Monday, April 26, 2021
Robotics, Ekso Bionics, Technology, Medical robotics, Science and technology, Prosthetics, Assistive technology, Powered exoskeleton

b'SYDNEY, Australia, April 25, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics, an industry leader in exoskeleton technology, with presence in Hong Kong, announces its partnership with Royal Rehab in Australia, further scaling the use of its robotic exoskeleton across the Asia Pacific region.\nWith Ekso Bionics\xe2\x80\x99 recent expansion plan in Asia Pacific, EksoNRs are now in Hong kong, Singapore, Malaysia, Taiwan and Australia.

Key Points: 
  • b'SYDNEY, Australia, April 25, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics, an industry leader in exoskeleton technology, with presence in Hong Kong, announces its partnership with Royal Rehab in Australia, further scaling the use of its robotic exoskeleton across the Asia Pacific region.\nWith Ekso Bionics\xe2\x80\x99 recent expansion plan in Asia Pacific, EksoNRs are now in Hong kong, Singapore, Malaysia, Taiwan and Australia.
  • Established in 1899, Royal Rehab is highly regarded for its state-wide specialist brain and spinal cord injury rehabilitation.
  • Royal Rehab is managed by an experienced and specialised team dedicated to maximising life skills, abilities, and independence.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.